【技术产业】BIO七月份十大新闻
发布于 2007-08-02 · 浏览 1557 · IP 浙江浙江
这个帖子发布于 17 年零 304 天前，其中的信息可能已发生改变或有所发展。
http://www.smartbrief.com/news/bio
1) FDA halts gene therapy clinical trial after patient death
The agency suspended a gene therapy study and said it's reviewing the safety of 28 other U.S. gene therapy studies that are using the same virus, called adeno-associated, after learning of a patient's death. Seattle-based Targeted Genetics Corp. notified the agency of the death, which occurred Tuesday during a clinical trial of an inflammatory arthritis drug candidate. Washington Post, The (07/26) New York Times, The (07/27)
2) Schwan: Alnylam could be next Genentech for Roche
Severin Schwan, in line to be Roche Holding's next CEO, says Alnylam Pharmaceuticals could become Roche's "second Genentech" in the U.S. and "opens up a new front in biotechnology" for the company. Alnylam, which recently signed a drug-development licensing deal with Roche, "offers us entry to a new technology platform to develop medications," Schwan said. Forbes (07/22)
3) Provenge delay sparks intense debate
Debate over the FDA's delay in approving Dendreon Corp.'s prostate cancer drug reflects the interests and stakes of biotech investors and patient advocacy groups, who have launched protests, letter-writing campaigns and blogs to criticize the agency's move. Two cancer specialists who recommended the FDA delay approval also have been criticized for their role in the process. Washington Post, The (07/06)
4) Researchers find biological switch linked to stress, obesity
Researchers looking at the relationship between chronic stress and a high fat diet in mice have found a neurochemical pathway that links stress to obesity. The team says blocking signals prevented fat accumulation and shrank fat deposits in mice experiments, and they hope to begin trials in people within two years. ClipSyndicate (07/03) Washington Post, The (07/02)
5) House committee approves patent reform bill
A patent reform bill opposed by the drug industry but supported by the technology sector was cleared for a vote by the full House. The legislation, aimed at streamlining the process for patent lawsuits, is similar to a bill due for consideration today in a Senate committee. Wall Street Journal, The (subscription required) (07/19) Boston Globe, The (07/19) International Herald Tribune (07/18)
6) House approves FDA legislation, skips follow-on biologics
The U.S. House of Representatives overwhelmingly approved a bill giving the FDA more authority for post-approval monitoring and requiring drug companies to pay an additional $225 million in user fees over five years. The House bill differs from a similar Senate bill in that it does not provide a path for FDA approval of follow-on biologics. Wall Street Journal, The (subscription required) (07/12) Reuters (07/11)
7) Novartis expresses interest in more takeovers
The Swiss pharmaceutical acknowledged it is interested in more takeovers to strengthen its portfolio and will look to buy companies that make health care products. Novartis AG recently bought rights to an experimental vaccine to fight nicotine addiction and said it will spend up to $890 million on two experimental cancer drugs. Financial Times (subscription required) (07/18) Bloomberg (07/17)
8) Lilly enters biotech business from within, not acquisitions
Eli Lilly is getting into the biotech business by building its own pipeline, rather than through acquisitions, and is working to establish itself as a major presence in the industry. The company said half of its new drugs entering trials this year will be biologics and it plans to bring a new biotech product to market every year starting in 2011. Wall Street Journal, The (subscription required) (07/31)
9) Synthetic biology emerging as new biotech focus
Now that genetic engineering has become routine in the biotech world, the new scientific attraction is synthetic biology that can change entire genomes. Efforts to create the first synthetic cell are likely to be seen not as creation of new life but as copying the genetic programming of evolution. New York Times, The (07/08)
10) Top 25 medical events, developments compiled by USA TODAY
USA TODAY's top 25 medical events include the HIV/AIDS and obesity epidemics, the development of statins, and an increase in cancer screenings. Also included were advances in medical technology, such as the polymerase chain reaction, automatic external defibrillators and laparoscopic surgery. USA TODAY (07/16)
1) FDA halts gene therapy clinical trial after patient death
The agency suspended a gene therapy study and said it's reviewing the safety of 28 other U.S. gene therapy studies that are using the same virus, called adeno-associated, after learning of a patient's death. Seattle-based Targeted Genetics Corp. notified the agency of the death, which occurred Tuesday during a clinical trial of an inflammatory arthritis drug candidate. Washington Post, The (07/26) New York Times, The (07/27)
2) Schwan: Alnylam could be next Genentech for Roche
Severin Schwan, in line to be Roche Holding's next CEO, says Alnylam Pharmaceuticals could become Roche's "second Genentech" in the U.S. and "opens up a new front in biotechnology" for the company. Alnylam, which recently signed a drug-development licensing deal with Roche, "offers us entry to a new technology platform to develop medications," Schwan said. Forbes (07/22)
3) Provenge delay sparks intense debate
Debate over the FDA's delay in approving Dendreon Corp.'s prostate cancer drug reflects the interests and stakes of biotech investors and patient advocacy groups, who have launched protests, letter-writing campaigns and blogs to criticize the agency's move. Two cancer specialists who recommended the FDA delay approval also have been criticized for their role in the process. Washington Post, The (07/06)
4) Researchers find biological switch linked to stress, obesity
Researchers looking at the relationship between chronic stress and a high fat diet in mice have found a neurochemical pathway that links stress to obesity. The team says blocking signals prevented fat accumulation and shrank fat deposits in mice experiments, and they hope to begin trials in people within two years. ClipSyndicate (07/03) Washington Post, The (07/02)
5) House committee approves patent reform bill
A patent reform bill opposed by the drug industry but supported by the technology sector was cleared for a vote by the full House. The legislation, aimed at streamlining the process for patent lawsuits, is similar to a bill due for consideration today in a Senate committee. Wall Street Journal, The (subscription required) (07/19) Boston Globe, The (07/19) International Herald Tribune (07/18)
6) House approves FDA legislation, skips follow-on biologics
The U.S. House of Representatives overwhelmingly approved a bill giving the FDA more authority for post-approval monitoring and requiring drug companies to pay an additional $225 million in user fees over five years. The House bill differs from a similar Senate bill in that it does not provide a path for FDA approval of follow-on biologics. Wall Street Journal, The (subscription required) (07/12) Reuters (07/11)
7) Novartis expresses interest in more takeovers
The Swiss pharmaceutical acknowledged it is interested in more takeovers to strengthen its portfolio and will look to buy companies that make health care products. Novartis AG recently bought rights to an experimental vaccine to fight nicotine addiction and said it will spend up to $890 million on two experimental cancer drugs. Financial Times (subscription required) (07/18) Bloomberg (07/17)
8) Lilly enters biotech business from within, not acquisitions
Eli Lilly is getting into the biotech business by building its own pipeline, rather than through acquisitions, and is working to establish itself as a major presence in the industry. The company said half of its new drugs entering trials this year will be biologics and it plans to bring a new biotech product to market every year starting in 2011. Wall Street Journal, The (subscription required) (07/31)
9) Synthetic biology emerging as new biotech focus
Now that genetic engineering has become routine in the biotech world, the new scientific attraction is synthetic biology that can change entire genomes. Efforts to create the first synthetic cell are likely to be seen not as creation of new life but as copying the genetic programming of evolution. New York Times, The (07/08)
10) Top 25 medical events, developments compiled by USA TODAY
USA TODAY's top 25 medical events include the HIV/AIDS and obesity epidemics, the development of statins, and an increase in cancer screenings. Also included were advances in medical technology, such as the polymerase chain reaction, automatic external defibrillators and laparoscopic surgery. USA TODAY (07/16)
最后编辑于 2022-10-09 · 浏览 1557
5 2 点赞
